S

Structure Therapeutics Inc
NASDAQ:GPCR

Watchlist Manager
Structure Therapeutics Inc
NASDAQ:GPCR
Watchlist
Price: 64.4883 USD 2.74%
Market Cap: 3.9B USD

Structure Therapeutics Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Structure Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
S
Structure Therapeutics Inc
NASDAQ:GPCR
Net Income (Common)
-$122.5m
CAGR 3-Years
-41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Income (Common)
$25.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income (Common)
$6B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Net Income (Common)
$9.8B
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Net Income (Common)
$19B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Net Income (Common)
$18.4B
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
23%
No Stocks Found

Structure Therapeutics Inc
Glance View

Market Cap
3.9B USD
Industry
Pharmaceuticals

Structure Therapeutics Inc., nestled in the realm of cutting-edge biotechnology, is crafting a compelling narrative of innovation and precision. Born from a commitment to tackling complex medical challenges, the company concentrates its expertise on the design and development of oral therapeutics for chronic respiratory and metabolic diseases. Structure Therapeutics leverages its capabilities in structure-based drug discovery—a sophisticated process that melds biology with computational tools to craft molecules with precise therapeutic potential. The company prides itself on its integrated platform which allows for the rapid development and optimization of novel small molecules, a testament to its scientific rigor and creative agility. In the pursuit of generating revenue, Structure Therapeutics strategically positions itself by advancing its pipeline projects through crucial stages of clinical development. By developing drugs that address substantial unmet medical needs, the company taps into large, financially lucrative markets, potentially capturing significant market share upon achieving regulatory approval. Additionally, Structure Therapeutics engages in partnerships and collaborations with other pharmaceutical entities, which not only provides financial inflows through upfront and milestone payments but also leverages external expertise to enrich their developmental strategies. This robust business model reflects its dual focus on pioneering impactful therapies while ensuring sustainable growth in a competitive and ever-evolving industry landscape.

GPCR Intrinsic Value
Not Available
S

See Also

What is Structure Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-122.5m USD

Based on the financial report for Dec 31, 2024, Structure Therapeutics Inc's Net Income (Common) amounts to -122.5m USD.

What is Structure Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-41%

Over the last year, the Net Income (Common) growth was -37%. The average annual Net Income (Common) growth rates for Structure Therapeutics Inc have been -41% over the past three years .

Back to Top